词条 | Hemolytic disease of the newborn (anti-RhE) |
释义 |
| name = HDN due to anti-RhE alloimmunization | | synonyms = | symptoms = | complications = | onset = | duration = | types = | causes = | risks = | diagnosis = | differential = | prevention = | treatment = | medication = | prognosis = | frequency = | deaths = }} Hemolytic disease of the newborn (anti-RhE) is caused by the anti-RhE antibody of the Rh blood group system. The anti-RhE antibody can be naturally occurring, or arise following immune sensitization after a blood transfusion or pregnancy. The anti-RhE antibody is quite common especially in the Rh genotype CDe/CDe; It usually only causes a mild hemolytic disease, but can cause a severe condition in the newborn. It can occur with other antibodies, usually the anti-Rhc antibody, which can also cause a severe hemolytic disease.[1] One study done by Moran et al., found that titers are not reliable for anti-E. Their most severe case of hemolytic disease of the newborn occurred with titers 1:2. Moran states that it would be unwise routinely to dismiss anti-E as being of little clinical consequence.[2] PresentationComplications
MechanismHemolytic disease of the fetus and newborn (HDN) is a condition where the passage of maternal antibodies results in the hemolysis of fetal/neonatal red cells. The antibodies can be naturally occurring such as anti-A, and anti-B, or immune antibodies developed following a sensitizing event.[9] Isoimmunization occurs when the maternal immune system is sensitized to red blood cell surface antigens. The most common causes of isoimmunization are blood transfusion, and fetal-maternal hemorrhage.[10] The hemolytic process can result in anemia, hyperbilirubinemia, neonatal thrombocytopenia, and neonatal neutropenia.[11] With the use of RhD Immunoprophylaxis, (commonly called Rhogam), the incidence of anti-D has decreased dramatically and other alloantibodies are now a major cause of HDN.[9] Antibody specificOne study done by Moran et al., found that titers are not reliable for anti-E. Their most severe case of hemolytic disease of the newborn occurred with titers 1:2. Moran states that it would be unwise routinely to dismiss anti-E as being of little clinical consequence.[2] In the case of anti-E, the woman should be checked around 28 weeks to see if she has developed anti-c as well.{{citation needed|date=February 2017}} TestingTesting for HDN involves blood work from both mother and father, and may also include assessment with amniocentesis and Middle Cerebral Artery scans. MotherBlood testing for the mother is called an Indirect Coombs Test (ICT) or an Indirect Agglutination Test (IAT). This test tells whether there are antibodies in the maternal plasma. If positive, the antibody is identified and given a titer. Critical titers are associated with significant risk of fetal anemia and hydrops.[1] Titers of 1:8 or higher is considered critical for Kell. Titers of 1:16 or higher are considered critical for all other antibodies. After critical titer is reached, care is based on MCA scans. If antibodies are low and have a sudden jump later in pregnancy, an MCA scan is warranted. If the titer undergoes a 4 fold increase, it should be considered significant regardless of if the critical value has been reached. It should be noted that maternal titers are not useful in predicting fetal anemia after the first affected gestation and should not be used for the basis of care.[12] Titers are tested monthly until 24 weeks, after which they are done every 2 weeks.[10] "In only 2 situations are patients not monitored identically to patients who are Rh sensitized. The first is that of alloimmunization to the c, E, or, C antigens. Some concern exists that hemolysis may occur in these patients with a lower than 1:16 titer. Thus, if the initial titer is 1:4 and stable but increases at 26 weeks' gestation to 1:8, assessment with MCA Doppler velocity at that point is reasonable. However, if the patient presents in the first trimester with a 1:8 titer that remains stable at 1:8 throughout the second trimester, continued serial antibody titers are appropriate. The second situation in which patients should not be treated identically to patients who are Rh D sensitized is that of Kell isoimmunization because several cases of severe fetal hemolysis with anti-Kell antibodies have occurred in the setting of low titers."[1] In the case of a positive ICT, the woman must carry a medical alert card or bracelet for life because of the risk of a transfusion reaction. FatherBlood is generally drawn from the father to help determine fetal antigen status.[13] If he is homozygous for the antigen, there is a 100% chance of all offspring in the pairing to be positive for the antigen and at risk for HDN. If he is heterozygous, there is a 50% chance of offspring to be positive for the antigen.[14] This test can help with knowledge for the current baby, as well as aid in the decision about future pregnancies. With RhD, the test is called the RhD genotype. With RhCE, and Kell antigen it is called an antigen phenotype.[15] FetusThere are 3 possible ways to test the fetal antigen status. Free Cell DNA, Amniocentesis, and Chorionic Villus Sampling (CVS). Of the three, CVS is no longer used due to risk of worsening the maternal antibody response. Once antigen status has been determined, assessment may be done with MCA scans.{{citation needed|date=February 2017}}
MCA scansMiddle cerebral artery - peak systolic velocity is changing the way sensitized pregnancies are managed.[17] This test is done noninvasively with ultrasound. By measuring the peak velocity of blood flow in the middle cerebral artery, a MoM (multiple of the median) score can be calculated. MoM of 1.5 or greater indicates severe anemia and should be treated with IUT.[18][17] InterventionThere are several intervention options available in early, mid and late pregnancies.{{citation needed|date=February 2017}} Early pregnancy
Mid to late pregnancy
After BirthTesting
In some cases, the direct coombs will be negative but severe, even fatal HDN can occur.[29] An indirect coombs needs to be run in cases of anti-C,[30] anti-c,[30] and anti-M. Anti-M also recommends antigen testing to rule out the presence of HDN.[21]
Treatment
Transfusion ReactionsOnce a woman has antibodies, she is at high risk for a transfusion reaction.[38] For this reason, she must carry a medical alert card at all times and inform all doctors of her antibody status. "Acute hemolytic transfusion reactions may be either immune-mediated or nonimmune-mediated. Immune-mediated hemolytic transfusion reactions caused by immunoglobulin M (IgM) anti-A, anti-B, or anti-A,B typically result in severe, potentially fatal complement-mediated intravascular hemolysis. Immune-mediated hemolytic reactions caused by IgG, Rh, Kell, Duffy, or other non-ABO antibodies typically result in extravascular sequestration, shortened survival of transfused red cells, and relatively mild clinical reactions. Acute hemolytic transfusion reactions due to immune hemolysis may occur in patients who have no antibodies detectable by routine laboratory procedures"[39] Summary of transfusion reactions in the US[40] See also
References1. ^1 2 3 4 {{EMedicine|article|273995|Erythrocyte Alloimmunization and Pregnancy}} 2. ^1 {{cite journal |doi=10.1111/j.1471-0528.2000.tb11662.x |pmid=11117776 |title=Anti-E in pregnancy |journal=BJOG |volume=107 |issue=11 |pages=1436–8 |year=2000 |last1=Moran |first1=P. |last2=Robson |first2=S. C. |last3=Reid |first3=M. M. }} 3. ^{{cite journal |doi=10.1038/sj.jp.7211157 |pmid=15578034 |title=Definition of the Clinical Spectrum of Kernicterus and Bilirubin-Induced Neurologic Dysfunction (BIND) |journal=Journal of Perinatology |volume=25 |issue=1 |pages=54–9 |year=2004 |last1=Shapiro |first1=Steven M }} 4. ^{{cite journal |doi=10.1016/j.siny.2005.10.010 |pmid=16338186 |title=Epidemiology of cerebral palsy |journal=Seminars in Fetal and Neonatal Medicine |volume=11 |issue=2 |pages=117–25 |year=2006 |last1=Blair |first1=Eve |last2=Watson |first2=Linda }} 5. ^{{cite journal |doi=10.1016/S0022-3476(48)80225-8 |pmid=18866937 |title=Clinical signs and development of survivors of kernicterus due to Rh sensitization |journal=The Journal of Pediatrics |volume=32 |issue=6 |pages=693–705 |year=1948 |last1=Lande |first1=Lottie }} 6. ^{{cite journal |pmid=20212966 |pmc=2828194 |year=1999 |author1=Mitchell |first1=S |title=Severe late anemia of hemolytic disease of the newborn |journal=Paediatrics & child health |volume=4 |issue=3 |pages=201–3 |last2=James |first2=A |doi=10.1093/pch/4.3.201}} 7. ^{{cite journal |pmid=10379500 |year=1999 |author1=Al-Alaiyan |first1=S |title=Late hyporegenerative anemia in neonates with rhesus hemolytic disease |journal=Journal of Perinatal Medicine |volume=27 |issue=2 |pages=112–5 |last2=Al Omran |first2=A |doi=10.1515/JPM.1999.014 }} 8. ^{{cite journal |doi=10.18203/2349-3291.ijcp20163704 |title=Late onset severe anemia due to rhesus isoimmunization |journal=International Journal of Contemporary Pediatrics |pages=1472–3 |year=2016 |last1=Jadala |first1=Hareesh |last2=v. |first2=Pooja |last3=k. |first3=Raghavendra |last4=m. |first4=Prithvish |last5=b. |first5=Srinivas }} 9. ^1 {{cite journal |doi=10.4103/0973-6247.75963 |pmid=21572705 |pmc=3082712 |title=Hemolytic disease of the fetus and newborn: Current trends and perspectives |journal=Asian Journal of Transfusion Science |volume=5 |issue=1 |pages=3–7 |year=2011 |last1=Basu |first1=Sabita |last2=Kaur |first2=Ravneet |last3=Kaur |first3=Gagandeep }} 10. ^1 2 3 {{cite journal |pmid=22439037 |pmc=3279102 |year=2009 |author1=Cacciatore |first1=A |title=Obstetric management in Rh alloimmunizated pregnancy |journal=Journal of prenatal medicine |volume=3 |issue=2 |pages=25–7 |last2=Rapiti |first2=S |last3=Carrara |first3=S |last4=Cavaliere |first4=A |last5=Ermito |first5=S |last6=Dinatale |first6=A |last7=Imbruglia |first7=L |last8=Recupero |first8=S |last9=La Galia |first9=T |last10=Pappalardo |first10=E. M. |last11=Accardi |first11=M. C. }} 11. ^1 2 3 4 {{cite journal |pmid=2494315 |year=1989 |author1=Koenig |first1=J. M. |title=Neutropenia and thrombocytopenia in infants with Rh hemolytic disease |journal=The Journal of Pediatrics |volume=114 |issue=4 Pt 1 |pages=625–31 |last2=Christensen |first2=R. D. |doi=10.1016/s0022-3476(89)80709-7}} 12. ^1 2 {{EMedicine|article|974349|Hemolytic Disease of Newborn|treatment}} 13. ^{{cite journal |doi=10.1111/j.1471-0528.2011.03028.x |pmid=21668766 |title=Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: Evaluation of a 7-year clinical experience |journal=BJOG: An International Journal of Obstetrics & Gynaecology |volume=118 |issue=11 |pages=1340–8 |year=2011 |last1=Scheffer |first1=PG |last2=Van Der Schoot |first2=CE |last3=Page-Christiaens |first3=Gcml |last4=De Haas |first4=M }} 14. ^Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects {{ISBN|978-0-08-092230-0}}{{page needed|date=February 2017}}{{full citation needed|date=February 2017}} 15. ^https://www.aacc.org/publications/cln/articles/2015/march/molecular-typing-for-red-blood-cell-antigens{{full citation needed|date=February 2017}} 16. ^{{cite journal |doi=10.1111/j.1537-2995.2007.01437.x |pmid=17958542 |title=Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma |journal=Transfusion |volume=47 |issue=11 |pages=2126–33 |year=2007 |last1=Finning |first1=Kirstin |last2=Martin |first2=Peter |last3=Summers |first3=Joanna |last4=Daniels |first4=Geoff }} 17. ^1 {{cite journal |doi=10.1056/NEJM200001063420102 |pmid=10620643 |title=Noninvasive Diagnosis by Doppler Ultrasonography of Fetal Anemia Due to Maternal Red-Cell Alloimmunization |journal=New England Journal of Medicine |volume=342 |issue=1 |pages=9–14 |year=2000 |last1=Mari |first1=Giancarlo |last2=Deter |first2=Russell L. |last3=Carpenter |first3=Robert L. |last4=Rahman |first4=Feryal |last5=Zimmerman |first5=Roland |last6=Moise |first6=Kenneth J. |last7=Dorman |first7=Karen F. |last8=Ludomirsky |first8=Avi |last9=Gonzalez |first9=Rogelio |last10=Gomez |first10=Ricardo |last11=Oz |first11=Utku |last12=Detti |first12=Laura |last13=Copel |first13=Joshua A. |last14=Bahado-Singh |first14=Ray |last15=Berry |first15=Stanley |last16=Martinez-Poyer |first16=Juan |last17=Blackwell |first17=Sean C. }} 18. ^{{cite journal |doi=10.1002/uog.1882 |pmid=15789353 |title=Middle cerebral artery peak systolic velocity for the diagnosis of fetal anemia: The untold story |journal=Ultrasound in Obstetrics and Gynecology |volume=25 |issue=4 |pages=323–30 |year=2005 |last1=Mari |first1=G. }} 19. ^{{cite journal |pmid=9085208 |year=1997 |author1=Voto |first1=L. S. |title=High-dose gammaglobulin (IVIG) followed by intrauterine transfusions (IUTs): A new alternative for the treatment of severe fetal hemolytic disease |journal=Journal of perinatal medicine |volume=25 |issue=1 |pages=85–8 |last2=Mathet |first2=E. R. |last3=Zapaterio |first3=J. L. |last4=Orti |first4=J |last5=Lede |first5=R. L. |last6=Margulies |first6=M |doi=10.1515/jpme.1997.25.1.85}} 20. ^{{cite journal |pmid=19003884 |year=2008 |author1=Novak |first1=D. J. |title=Plasmapheresis and intravenous immune globulin for the treatment of D alloimmunization in pregnancy |journal=Journal of Clinical Apheresis |volume=23 |issue=6 |pages=183–5 |last2=Tyler |first2=L. N. |last3=Reddy |first3=R. L. |last4=Barsoom |first4=M. J. |doi=10.1002/jca.20180 }} 21. ^1 {{cite journal |doi=10.4103/0973-6247.150968 |pmid=25722586 |pmc=4339947 |title=Maternal anti-M induced hemolytic disease of newborn followed by prolonged anemia in newborn twins |journal=Asian Journal of Transfusion Science |volume=9 |issue=1 |pages=98–101 |year=2015 |last1=Arora |first1=Satyam |last2=Doda |first2=Veena |last3=Maria |first3=Arti |last4=Kotwal |first4=Urvershi |last5=Goyal |first5=Saurabh }} 22. ^{{cite journal |pmid=17045529 |year=2006 |author1=Palfi |first1=M |title=A case of severe Rh (D) alloimmunization treated by intensive plasma exchange and high-dose intravenous immunoglobulin |journal=Transfusion and Apheresis Science |volume=35 |issue=2 |pages=131–6 |last2=Hildén |first2=J. O. |last3=Matthiesen |first3=L |last4=Selbing |first4=A |last5=Berlin |first5=G |doi=10.1016/j.transci.2006.07.002 }} 23. ^{{cite journal |pmid=17306655 |year=2007 |author1=Ruma |first1=M. S. |title=Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization |journal=American Journal of Obstetrics and Gynecology |volume=196 |issue=2 |pages=138.e1–6 |last2=Moise Jr |first2=K. J. |last3=Kim |first3=E |last4=Murtha |first4=A. P. |last5=Prutsman |first5=W. J. |last6=Hassan |first6=S. S. |last7=Lubarsky |first7=S. L. |doi=10.1016/j.ajog.2006.10.890 }} 24. ^{{cite journal |doi=10.1007/s40556-016-0072-4 |pmid=26811110 |title=Intrauterine Transfusion |journal=Journal of Fetal Medicine |volume=27 |issue=3 |pages=505 |year=2016 |last1=Deka |first1=Dipika }} 25. ^1 2 http://www.uptodate.com/contents/intrauterine-fetal-transfusion-of-red-cells{{full citation needed|date=February 2017}} 26. ^https://www.mombaby.org/wp-content/uploads/2016/03/UNC-Isoimmunization-Detection-Prevention.pdf{{full citation needed|date=February 2017}} 27. ^{{cite journal |doi=10.1002/uog.2837 |pmid=16941575 |title=Management of Kell isoimmunization — evaluation of a Doppler-guided approach |journal=Ultrasound in Obstetrics and Gynecology |volume=28 |issue=6 |pages=814–20 |year=2006 |last1=Rimon |first1=E. |last2=Peltz |first2=R. |last3=Gamzu |first3=R. |last4=Yagel |first4=S. |last5=Feldman |first5=B. |last6=Chayen |first6=B. |last7=Achiron |first7=R. |last8=Lipitz |first8=S. }} 28. ^1 2 3 4 5 {{cite journal |doi=10.1136/adc.2005.076794 |pmid=17337672 |pmc=2675453 |title=Haemolytic disease of the newborn |journal=Archives of Disease in Childhood: Fetal and Neonatal Edition |volume=92 |issue=2 |pages=F83–8 |year=2007 |last1=Murray |first1=N. A |last2=Roberts |first2=I. A G }} 29. ^{{cite journal |pmid=7655573 |year=1995 |author1=Heddle |first1=N. M. |title=Three examples of Rh haemolytic disease of the newborn with a negative direct antiglobulin test |journal=Transfusion medicine (Oxford, England) |volume=5 |issue=2 |pages=113–6 |last2=Wentworth |first2=P |last3=Anderson |first3=D. R. |last4=Emmerson |first4=D |last5=Kelton |first5=J. G. |last6=Blajchman |first6=M. A. |doi=10.1111/j.1365-3148.1995.tb00197.x}} 30. ^1 2 {{EMedicine|article|974349|Hemolytic Disease of Newborn|workup}} 31. ^https://www.ucsfbenioffchildrens.org/pdf/manuals/42_Hemol.pdf{{full citation needed|date=February 2017}} 32. ^1 {{cite journal |pmid=14413526 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=14413526 |year=1960 |author1=Lalezari |first1=P |title=Neonatal neutropenia due to maternal isoimmunization |journal=Blood |volume=15 |pages=236–43 |last2=Nussbaum |first2=M |last3=Gelman |first3=S |last4=Spaet |first4=T. H. }} 33. ^1 {{cite journal |pmid=23802744 |year=2013 |author1=Rath |first1=M. E. |title=Iron status in infants with alloimmune haemolytic disease in the first three months of life |journal=Vox Sanguinis |volume=105 |issue=4 |pages=328–33 |last2=Smits-Wintjens |first2=V. E. |last3=Oepkes |first3=D |last4=Walther |first4=F. J. |last5=Lopriore |first5=E |doi=10.1111/vox.12061 }} 34. ^1 2 {{cite journal |pmid=15231951 |url=http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=15231951 |year=2004 |author1=American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. |title=Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation |journal=Pediatrics |volume=114 |issue=1 |pages=297–316 |doi=10.1542/peds.114.1.297}} 35. ^{{cite journal |pmid=20092394 |year=2010 |author1=Onesimo |first1=R |title=Intravenous Immunoglobulin therapy for anti-E hemolytic disease in the newborn |journal=The Journal of Maternal-Fetal & Neonatal Medicine |volume=23 |issue=9 |pages=1059–61 |last2=Rizzo |first2=D |last3=Ruggiero |first3=A |last4=Valentini |first4=P |doi=10.3109/14767050903544751 }} 36. ^{{cite journal |doi=10.1136/fn.88.1.F6 |pmid=12496219 |pmc=1755998 |title=Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn |journal=Archives of Disease in Childhood: Fetal and Neonatal Edition |volume=88 |issue=1 |pages=F6–10 |year=2003 |last1=Gottstein |first1=R }} 37. ^{{EMedicine|article|974349|Hemolytic Disease of Newborn|followup}} 38. ^{{cite journal |doi=10.1159/000154811 |pmid=21512623 |pmc=3076326 |title=Hemolytic Transfusion Reactions |journal=Transfusion Medicine and Hemotherapy |volume=35 |issue=5 |pages=346–353 |year=2008 |last1=Strobel |first1=Erwin }} 39. ^{{EMedicine|article|206885|Transfusion Reactions}} 40. ^http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm302847.htm{{full citation needed|date=February 2017}} Further reading
External links{{Medical resources| ICD10 = {{ICD10|P|55|8|p|50}} | ICD9 = {{ICD9|773.2}} }}{{HDN}}{{DEFAULTSORT:Hemolytic Disease Of The Newborn (Anti-Rhe)}}Гемолитическая желтуха новорождённых 3 : Haemorrhagic and haematological disorders of fetus and newborn|Disorders originating in the perinatal period|Transfusion medicine |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。